Agile pulls off a $55M IPO after taking a 50% haircut

Damian Garde Princeton, NJ's Agile Therapeutics finally made its way onto Wall Street, pulling in $ 55 million after halving its expected share price. FierceBiotech News

Forest CEO Saunders to lead combined company after Actavis buyout

Alok Saboo FierceBiotech News

Reckitt is indeed after Merck’s consumer unit, and it’s ready for a close race

Carly Helfand As Reuters reported this weekend, Reckitt and Germany's Bayer have emerged as front-runners for the unit, which could go for $ 13.5 billion–or higher, ...

Aastrom surges after acquiring Sanofi’s cell therapies

John Carroll A little more than a year after reorganizing the company and slashing staff in the wake of a Phase III failure, Ann Arbor, MI-based Aastrom Biosciences has acquired Sanofi's ...

FDA lifts its hold on Juno’s cutting-edge cancer drug after deaths trigger delay

John Carroll The FDA has lifted a clinical hold placed on a study at Memorial Sloan-Kettering of Juno Therapeutics' cutting-edge approach to treating cancer using genetically tailored ...

Chimerix CEO Moch steps down after compassionate-use controversy

Alok Saboo FierceBiotech News

Eisai readies applications for thyroid cancer drug after SFJ delivers PhIII success

John Carroll FierceBiotech News

Aveo’s cancer drug circles the drain after a scuttled Phase II trial

Damian Garde Aveo Oncology and Astellas Pharma are shutting down a Phase II study of tivozanib in breast cancer after failing to enroll enough patients, the partners announced. FierceBiotech ...

Progenics tanks after two trial deaths cast doubt on its lead program

Damian Garde Two patients died of sepsis in a Phase II trial of Progenics Pharmaceuticals' in-development prostate cancer treatment, spurring concern that the drug is too toxic ...

Teva stands by its MS pill after yet another setback

Damian Garde European regulators recommended against Teva Pharmaceutical's laquinimod, marring the Isreali company's odds of crossing the finish line with its once-promising ...

PTC slammed after EMA spurns its bid for early OK of DMD drug

John Carroll Shares of PTC Therapeutics took a hit this morning, dropping about 20% after the European Medicines Agency threw its considerable weight against the biotech's application ...

Merck is cutting 150 in its Saphris sales team after selling the drug to Forest for $240M

Eric Palmer Merck early in December agreed to sell the rights to its antipsychotic drug Saphris to Forest Laboratories for $ 240 million. The move not only gave it a small cash boost, ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS